Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open-label case series

Journal of Clinical Psychiatry

Volumn 60, Issue 8, 1999, Pages 524-527

  Weiss, Erica L ^a,c   Potenza, Marc N ^a   McDougle, Christopher J ^b   Epperson, C Neill ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; OLANZAPINE; PAROXETINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OBSESSION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0032854930     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0804     Document Type: Article

References (18)

1. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive-compulsive disorder: implications for treatment and pathogenesis. In: Dunner DL, ed. Psychiatric Clinics of North America, vol 16. 4th ed. Philadelphia, Pa: Saunders; 1993:749-766
2. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-43
3. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184
4. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150:647-649
5. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-654
6. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308
7. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-1814
8. Potenza MN, McDougle CJ. Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs 1998;9:213-232
9. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
10. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
11. Ravizza L, Barzega G, Bellino S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996;32:677-682
12. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122
13. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. In press
14. Baker RW, Ames D, Umbricht DSG, et al. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull 1996;32:89-93
15. Potenza MN, Wasylink S, Longhurst JG, et al. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychopharmacol 1998;18:423-424
16. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
17. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), II: validity. Arch Gen Psychiatry 1989; 46:1012-1016
18. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-17